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Short Communication
Lactate dehydrogenase is not a useful marker for relapse in
patients on surveillance for stage I germ cell tumours
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As part of surveillance protocols for stage I germ cell tumours, many centres routinely measure human chorionic gonadotrophin
(HCG), alpha feto-protein (AFP) as well as lactate dehydrogenase (LDH). In conjunction with regular imaging and clinical
examination, does routine measurement of LDH add anything to our relapse/pick up rate? Records of 494 patients at Mount Vernon
Hospital who relapsed on surveillance between 1985 and 2005 were examined. Of the 494 patients who relapsed, 125 had raised
LDH at the time of relapse. 112 of these had a concurrent rise in either AFP, HCG or both, 11 had their disease detected on CT
before the rise in LDH, one had a clinically palpable para-aortic mass and the final patient complained of back pain and his
retroperitoneal disease was thus discovered on imaging. Routine measurement of LDH in patients on surveillance for stage I germ cell
tumours does not add to the early detection of relapse.
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A high proportion of patients with stage I testicular germ cell
tumours are managed by close surveillance post-orchidectomy
(Read et al, 1992). The surveillance protocol consists of regular
physical examinations, chest X-rays, CT scans and measurement of
tumour markers. All protocols include measurement of human
chorionic gonadotrophin (HCG) and alpha feto-protein (AFP).
Although lactate dehydrogenase (LDH) is elevated in more than
50% of patients with germ cell tumours and is an important
prognostic indicator (Group IGCU, 1997), it is not clear whether it
is valuable in surveillance. The majority of patients in our
surveillance programme at Mount Vernon Hospital have had
regular LDH measurements and we have therefore performed a
retrospective analysis to determine whether regular measurements
of LDH lead to earlier diagnosis of relapse than that discovered by
the other components of the surveillance protocol.
MATERIALS AND METHODS
The notes, blood results and imaging of 494 patients with stage I
germ cell tumours who relapsed while on surveillance at Mount
Vernon Hospital between 1985 and 2005 were reviewed.
The method(s) used to identify relapse was identified to
ascertain how often a rise in LDH helped to detect relapse.
RESULTS
The majority of patients had nonseminomatous germ cell
tumours (399 patients (81%)) and the remainder were seminomas
(95 patients (19%)). A total of 125 had a raised LDH at the
time of relapse, but 112 had a concurrent rise in either AFP,
HCG or both. Of the other 13, 11 were seminomas and
disease recurrence had already been detected on routine surveil-
lance CT scans before the rise in LDH. Of the remaining
two patients, disease relapse was identified clinically alongside
the rise in LDH. One patient had a palpable para-aortic mass,
the other complained of back pain and para-aortic disease
was subsequently identified on imaging. There were no cases
in which a rise in LDH alone was the only marker of disease
relapse.
During follow-up, a further 26 patients had a benign cause for a
rise in their LDH. Eighteen were owing to intercurrent infections
and the LDH normalised spontaneously. One had a familial,
persistently raised LDH. The final seven had an acute rise in LDH
owing to heavy alcohol intake just before their blood test. Repeat
samples within 1 week were entirely normal.
DISCUSSION
The level of serum LDH has independent prognostic significance
in patients with advanced germ cell tumours, reflected within
the IGCCCG grouping. Increases in the serum concentration
are a reflection of tumour burden, growth rate and cellular
proliferation.
Lactate dehydrogenase is comprised of multiple isoenzymes, but
in practice, the combined isoenzyme value is used for clinical
decision making (Von Eyben, 2001). Increased serum LDH
concentrations are observed in approximately 60% of NSGCTs
with advanced disease and in 80% of patients with advanced
seminoma.
In a paper published in Cancer (Lippert and Javadpour, 1981),
LDH in 80 patients with testicular germ cell tumours was reviewed.
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sSerum LDH was found to be elevated more frequently with
increasing tumour bulk (78% of patients with stage III disease
and only 26% of stage II patients). It may therefore be that with
vigilant surveillance, relapses are detected at a very early stage and
tumour bulk may be minimal. Hence a rise in LDH is less
commonly seen.
CONCLUSION
Routine measurement of LDH in patients on surveillance for stage
I germ cell tumours does not add to the early detection of relapse.
Lactate dehydrogenase remains important in determining
prognosis.
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